The amount of the transaction was not disclosed.
The agreement will allow Silicon Biosystems to accelerate its research and make available new personalized therapeutic and diagnostic applications. It will remain a stand-alone company.
Led by Giuseppe Giorgini, President and CEO, Silicon Biosystems has patented DEPArray™, which can automatically isolate rare single cancer cells in blood while keeping them intact, alive and capable of reproducing themselves by using the principles of dielectrophoresis.
The company has U.S. Laboratory in San Diego.
Menarini has over 16,000 employees worldwide and a presence in more than 100 countries in Europe, Asia, Latin America, Africa and the Middle East. It has a 2012 turnover of more than €3.2 billion ($4.2 billion).